{"database": "lobbying", "table": "lobbying_activities", "rows": [[2471012, "fbad7239-e33e-41a4-b0f4-bd3414d5d732", "Q2", "BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.", 6382, "BLUE CROSS AND BLUE SHIELD OF FLORIDA INC", 2020, "second_quarter", "PHA", "Opioids; CREATES Act; Drug Pricing\n\nHR 4712 (116th Congress), Fairness in Orphan Drug Exclusivity Act, by Rep. Madeleine Dean (D-PA). Amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs.\n\nHR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration.\n\nHR 5663 (116th Congress), Safeguarding Therapeutics Act, by Rep. Brett Guthrie (R-KY). Give authority to the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to destroy counterfeit devices.\n\nHR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin.\n\nHR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain.\n\nHR 5894 (116th Congress), Transparency in Prescription Drug Advertising Act, by Rep. Sharice Davids (D-KS). Directs the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs.\n\nHR 5927 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on unsafe Chinese pharmaceuticals and to empower the Food and Drug Administration to mandate drug recalls in the case of critical contamination.\n\nHR 5982 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on Chinese pharmaceuticals and to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination.\n\nHR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). Require group health plans and health insurance issuers offering group or individual health insurance coverage to provide benefits under such plan or such coverage for a 30-day refill of prescription drugs to individuals who reside in emergency areas during emergency periods.\n\nHR 6731 (116th Congress), Securing Americas Pharmaceutical Supply Chain Act, by Rep. Pete Stauber (R-MN). Require executive agencies to purchase pharmaceuticals from the United States.", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office", null, 350000, 0, 0, "2020-07-17T11:08:04.047000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2471012"], "units": {}, "query_ms": 23.010608972981572, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}